BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 16, Issue 11
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (1)
All Articles published online
The chart showing PDF series, HTML series, Tables (1-5) series.
Item 
Count 
PDF0
HTML0
Tables (1-5)0
 Sum=0
Nov 24, 2025 (publication date) through Nov 21, 2025
Times Cited of This Article
  • Times Cited  (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study
Copyright ©The Author(s) 2025.
World J Clin Oncol. Nov 24, 2025; 16(11): 112349
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.112349
Table 1 Characteristics of the patients from this study, n (%)
Characteristic
BrC patients
n = 71
Age at diagnosis, mean ± SD54.06 ± 10.75
Patients with relatives with cancer
First-degree relative22 (31.0)
Second-degree relative10 (14.1)
With no relatives39 (54.9)
Subtype of BrC
Lobular13 (18.3)
Ductal37 (52.1)
Mixed5 (7.0)
Not determined16 (22.5)
BrC hormone receptor status
HR+38 (53.5)
HER+9 (12.7)
Triple-negative BrC5 (7.0)
Triple-positive BrC13 (18.3)
Not determined6 (8.5)
Molecular subtype
Luminal A36 (50.7)
Luminal B13 (18.3)
HER29 (12.7)
Triple negative5 (7.0)
Not determined8 (11.3)
BrC: Breast cancer; HR+: Hormone receptor positive; HER+: Human epidermal growth factor positive; HER2: Human epidermal growth factor receptor 2; Triple-positive BrC: Hormone receptor positive, human epidermal growth factor positive and progesterone receptor positive; Triple Negative BrC: Hormone receptor negative, human epidermal growth factor negative and progesterone receptor negative.
Full Size Table
Table 2 rs11614913, rs2682818 and rs73262897 allelic and genotypic frequencies of patients with breast cancer and their association with its development in western Mexican population according to the genetic models, n (%)
Genetic model
Genotypes
BrC cases (n = 71)
Controls (n = 215)
OR
95%CI
P value
rs11614913 C>T
MCC/C27 (38)77 (36)1.00--
C/T26 (37)102 (47)0.72960.3932-1.34390.3091
T/T18 (25)36 (17)1.42590.6970-2.91710.3312
DoC/C27 (38)77 (36)1.00--
C/T + T/T44 (62)138 (64)0.90930.5223-1.58290.7367
ReC/C + C/T53 (75)179 (83)1.00--
T/T18 (25)36 (17)1.68870.8873-3.21730.1105
ODC/C + T/T45 (63)113 (53)1.00--
C/T26 (37)102 (47)0.64010.3685-1.11170.1132
L-ad---0.890.61-1.280.52
Allele
C80 (56)256 (60)0.890.7770-1.67320.5024
T62 (44)174 (40)
rs2682818 C>A
MCC/C67 (94)175 (81)1.00--
C/A4 (6)40 (19)0.26120.0900-0.75820.0135a,b
A/A0 (0)0 (0)NDNDND
Allele
C138 (97)390 (91)0.28260.0993-0.80440.0179a,b
A4 (3)40 (9)
rs73262897 G>A
MCG/G54 (76)171 (79.5)1.00--
G/A17 (24)43 (20)1.25190.6605-2.37300.4910
A/A0 (0)1 (0.5)NDNDND
Allele
G125 (88)385 (90)1.16360.6428-2.10610.6168
A17 (12)45 (10)
aP < 0.05.
bP < 0.025 Bonferroni correction.
Genetics models of rs2682818 and rs73262897 could not be analyzed because of the absence of the genotype A/A and A/A, respectively, in breast cancer cases. BrC: Breast cancer; OR: Odds ratio; CI: Confidence interval; MC: Multiple comparison; Do: Dominant model; Re: Recessive model; OD: Over-dominant model; L-ad: Log-additive model; ND: Not determined.
Full Size Table
Table 3 Association between rs11614913 with histological and immunohistochemical subtypes of breast cancer, n (%)
rs11614913 C>T
Cases
Control
Model comparison
OR (95%CI)
P value
Breast cancer ductal
Genotype-n = 37n = 215-C/C vs C/T0.7296 (0.3932-1.3439)0.3091
C/C15 (40)77 (36)MCC/C vs T/T1.4259 (0.6970-2.9171)0.3312
C/T11 (30)102 (47)-C vs T1.1402 (0.7770-1.6732)0.5024
T/T11 (30)36 (17)DoC/C vs C/T + T/T0.8184 (0.4011-1.6696)0.5816
Allele-ReC/C + C/T vs T/T2.1036 (0.9541-4.6383)0.0653
C41 (55)256 (60)ODC/C + T/T vs C/T0.4687 (0.2205-0.9963)0.0489a
T33 (45)174 (40)L-ad0.85 (0.53-1.38)0.5200
Breast cancer lobular
Genotype-n = 13n = 215MCC/C vs C/T--
C/C6 (36)77 (36)MCC/C vs T/T--
C/T5 (47)102 (47)-C vs T--
T/T2 (15)36 (17)DoC/C vs C/T + T/T--
Allele-ReC/C + C/T vs T/T--
C17 (65)256 (60)ODC/C + T/T vs C/T0.6924 (0.2195-2.1845)0.5306
T9 (35)174 (40)L-ad1.28 (0.56-2.91)0.5600
Breast cancer mixed
Genotype-n = 5n = 215-C/C vs C/T--
C/C1 (20)77 (36)MCC/C vs T/T--
C/T4 (80)102 (47)-C vs T--
T/T0 (0)36 (17)DoC/C vs C/T + T/T--
Allele-ReC/C + C/T vs T/T--
C6 (60)256 (60)ODC/C + T/T vs C/T--
T4 (40)174 (40)L-ad--
Breast cancer HR+/LA
Genotype-n = 36n = 215-C/C vs C/T1.5139 (0.6968-3.2891)0.2948
C/C16 (44)77 (36)MCC/C vs T/T0.8021 (0.2897-2.2206)0.6712
C/T14 (39)102 (47)C vs T0.8316 (0.4954-1.3960)0.4853
T/T6 (17)36 (17)DoC/C vs C/T + T/T0.6975 (0.3415-1.4244)0.3227
Allele-ReC/C + C/T vs T/T0.9944 (0.3858-2.5632)0.9908
C46 (64)256 (60)ODC/C + T/T vs C/T0.7050 (0.3426-1.4506)0.3424
T26 (36)174 (40)L-ad1.20 (0.72-1.99)0.4900
Breast cancer TP/LB
Genotype-n = 13n = 215-C/C vs C/T--
C/C4 (31)77 (36)MCC/C vs T/T--
C/T3 (23)102 (47)-C vs T2.0063 (0.9001-4.4718)0.0886
T/T6 (46)36 (17)DoC/C vs C/T + T/T--
Allele-ReC/C + C/T vs T/T--
C11 (42)256 (60)ODC/C + T/T vs C/T0.33 (0.089-1.241)0.1013
T15 (58)174 (40)L-ad0.51 (0.230-1.130)0.0940
Breast cancer HER2+
Genotype-n = 9n = 215-C/C vs C/T--
C/C8 (89)77 (36)MCC/C vs T/T--
C/T1 (11)102 (47)-C vs T1.4713 (0.5725-3.7808)0.4226
T/T0 (0)36 (17)DoC/C vs C/T + T/T--
Allele-ReC/C + C/T vs T/T--
C17 (94)256 (60)ODC/C + T/T vs C/T--
T1 (6)174 (40)L-ad0.69 (0.27-1.74)0.4300
Breast cancer TN
Genotype-n = 5n = 215-C/C vs C/T--
C/C5 (100)77 (36)MCC/C vs T/T--
C/T0 (0)102 (47)-C vs T--
T/T0 (0)36 (17)DoC/C vs C/T + T/T--
Allele-ReC/C + C/T vs T/T--
C10 (100)256 (60)ODC/C + T/T vs C/T--
T0 (0)174 (40)L-ad0.69 (0.20-2.37)0.5500
aP < 0.05.
OR: Odds ratio; CI: Confidence interval; MC: Multiple comparison; Do: Dominant model; Re: Recessive model; OD: Over-dominant model; L-ad: Log-additive model; HR+: Hormone receptor positive; LA: Luminal A; TP: Triple positive; LB: Luminal B; HER2+: Human epidermal growth factor 2 positive.
Full Size Table
Table 4 Association between rs2682818 with histological and immunohistochemical subtypes of breast cancer, n (%)
rs2682818 C>A
Cases
Control
Model comparison
OR (95%CI)
P value
Breast cancer ductal
Genotype-n = 37n = 215-C/C vs C/A0.1215 (0.0162-0.9129)0.0405a
C/C36 (97)175 (81)MCC/C vs A/A--
C/A1 (3)40 (19)-C vs A0.1336 (0.0181-0.9869)0.0485a
A/A0 (0)0 (0)DoC/C vs C/A + A/A--
AlleleReC/C+C/A vs A/A--
C73 (99)390 (91)ODC/C+A/A vs C/A--
A1 (1)40 (9)L-ad--
Breast cancer lobular
Genotype-n = 13n = 215-C/C vs C/A--
C/C12 (92)175 (81)MCC/C vs A/A--
C/A1 (8)40 (19)-C vs A--
A/A0 (0)0 (0)DoC/C vs C/A + A/A--
Allele-ReC/C+C/A vs A/A--
C25 (96)390 (91)ODC/C+A/A vs C/A--
A1 (4)40 (9)L-ad--
Breast cancer mixed
Genotype-n = 5n = 215-C/C vs C/A--
C/C5 (100)175 (81)MCC/C vs A/A--
C/A1 (8)40 (19)-C vs A--
A/A0 (0)0 (0)DoC/C vs C/A + A/A--
Allele-ReC/C + C/A vs A/A--
C10 (100)390 (91)ODC/C + A/A vs C/A--
A0 (0)40 (9)L-ad--
Breast cancer HR+/LA
Genotype-n = 36n = 215-C/C vs C/A0.1250 (0.0166-0.9397)0.0433a
C/C35 (97)175 (81)MCC/C vs A/A--
C/A1 (3)40 (19)-C vs A0.1373 (0.0186-1.0151)0.0517
A/A0 (0)0 (0)DoC/C vs C/A + A/A--
Allele-ReC/C + C/A vs A/A--
C71 (99)390 (91)ODC/C + A/A vs C/A--
A1 (1)40 (9)L-ad--
Breast cancer TP/LB
Genotype-n = 13n = 215-C/C vs C/A--
C/C12 (92)175 (81)MCC/C vs A/A--
C/A1 (8)40 (19)-C vs A--
A/A0 (0)0 (0)DoC/C vs C/A + A/A--
Allele-ReC/C + C/A vs A/A--
C25 (96)390 (91)ODC/C + A/A vs C/A--
A1 (4)40 (9)L-ad--
Breast cancer HER2+
Genotype-n = 9n = 215-C/C vs C/A--
C/C8 (89)175 (81)MCC/C vs A/A--
C/A1 (11)40 (19)-C vs A--
A/A0 (0)0 (0)DoC/C vs C/A + A/A--
Allele-ReC/C + C/A vs A/A--
C17 (94)390 (91)ODC/C + A/A vs C/A--
A1 (6)40 (9)L-ad--
Breast cancer TN
Genotype-n = 5n = 215-C/C vs C/A--
C/C5 (100)175 (81)MCC/C vs A/A--
C/A0 (0)40 (19)-C vs A--
A/A0 (0)0 (0)DoC/C vs C/A + A/A--
Allele-ReC/C + C/A vs A/A--
C10 (100)390 (91)ODC/C + A/A vs C/A--
A0 (0)40 (9)L-ad--
aP < 0.05.
OR: Odds ratio; CI: Confidence interval; MC: Multiple comparison; Do: Dominant model; Re: Recessive model; OD: Over-dominant model; L-ad: Log-additive model; HR+: Hormone receptor positive; LA: Luminal A; TP: Triple positive; LB: Luminal B; HER2+: Human epidermal growth factor 2 positive.
Full Size Table
Table 5 Association between rs73262897 with histological and immunohistochemical subtypes of breast cancer, n (%)
rs73262897 G>A
Cases
Control
Model comparison
OR (95%CI)
P value
Breast cancer ductal
Genotype-n = 37n = 215-G/G vs G/A1.0970 (0.4683-2.5696)0.8311
G/G29 (78)171 (80)MCG/G vs A/A--
G/A8 (22)43 (20)-G vs A1.0370 (0.4678-2.2990)0.9287
A/A0 (0)1 (0)DoG/G vs G/A + A/A--
Allele-ReG/G + G/A vs A/A--
G66 (89)385 (90)ODG/G + A/A vs G/A--
A8 (11)45 (10)L-ad--
Breast cancer lobular
Genotype-n = 13n = 215-G/G vs G/A--
G/G10 (77)171 (80)MCG/G vs A/A--
G/A3 (23)43 (20)-G vs A--
A/A0 (0)1 (0)DoG/G vs G/A + A/A--
Allele-ReG/G + G/A vs A/A--
G23 (88)385 (90)ODG/G + A/A vs G/A--
A3 (12)45 (10)L-ad--
Breast cancer mixed
Genotype-n = 5n = 215-G/G vs G/A--
G/G2 (40)171 (80)MCG/G vs A/A--
G/A3 (60)43 (20)-G vs A--
A/A0 (0)1 (0)DoG/G vs G/A + A/A--
Allele-ReG/G + G/A vs A/A--
G7 (70)385 (90)ODG/G + A/A vs G/A--
A3 (30)45 (10)L-ad--
Breast cancer HR+/LA
Genotype-n = 36n = 215-G/G vs G/A1.5295 (0.6857-3.4119)0.2992
G/G26 (72)171 (80)MCG/G vs A/A--
G/A10 (28)43 (20)-G vs A1.3799 (0.6611-2.8802)0.3910
A/A0 (0)1 (0)DoG/G vs G/A + A/A--
Allele-ReG/G + G/A vs A/A--
G62 (86)385 (90)ODG/G + A/A vs G/A--
A10 (14)45 (10)L-ad--
Breast cancer TP/LB
Genotype-n = 13n = 215-G/G vs G/A--
G/G10 (77)171 (80)MCG/G vs A/A--
G/A3 (23)43 (20)-G vs A--
A/A0 (0)1 (0)DoG/G vs G/A + A/A--
Allele-ReG/G + G/A vs A/A--
G23 (88)385 (90)ODG/G + A/A vs G/A--
A3 (12)45 (10)L-ad--
Breast cancer HER2+
Genotype-n = 9n = 215-G/G vs G/A--
G/G7 (78)171 (80)MCG/G vs A/A--
G/A2 (22)43 (20)-G vs A--
A/A0 (0)1 (0)DoG/G vs G/A + A/A--
Allele-ReG/G + G/A vs A/A--
G16 (89)385 (90)ODG/G + A/A vs G/A--
A2 (11)45 (10)L-ad--
Breast cancer TN
Genotype-n = 5n = 215-G/G vs G/A--
G/G5 (100)171 (80)MCG/G vs A/A--
G/A0 (0)43 (20)-G vs A--
A/A0 (0)1 (0)DoG/G vs G/A + A/A--
Allele-ReG/G + G/A vs A/A--
G10 (100)385 (90)ODG/G + A/A vs G/A--
A0 (0)45 (10)L-ad--
aP < 0.05.
OR: Odds ratio; CI: Confidence interval; MC: Multiple comparison; Do: Dominant model; Re: Recessive model; OD: Over-dominant model; L-ad: Log-additive model; HR+: Hormone receptor positive; LA: Luminal A; TP: Triple positive; LB: Luminal B; HER2+: Human epidermal growth factor 2 positive.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345